Aster DM Healthcare announced its investor presentation for Q3FY26. The combined entity saw a 15% YoY revenue growth reaching INR 2,366 crores. Total patient volumes grew by 9% YoY, reaching 1.97 Mn. The merged entity exhibited a robust 22% YoY EBITDA growth to INR 503 crores. The company added 560+ beds, bringing the total to 10,620+.
Q3FY26 Performance Highlights
Aster DM Healthcare’s combined entity demonstrated strong YoY revenue growth, aided by steady patient volume growth:
- Combined entity revenue increased by 15% YoY, reaching INR 2,366 crores.
- Total patient volumes increased by 9% YoY, reaching 1.97 Mn.
- CONGO mix increased by approximately 150 bps, reaching 54.4%.
EBITDA Growth
Robust EBITDA growth reflects operational leverage and effective cost management:
- The merged entity exhibited a robust 22% YoY EBITDA growth to INR 503 crores.
- EBITDA margins stood at 21%.
Capacity Expansion
The company added 560+ beds, taking total bed capacity to 10,620+ as of December 31, 2025.
Merger Update
- Post receipt of no-objection letter from stock exchanges/SEBI, the company filed the application to NCLT on December 11, 2025.
- As per NCLT direction, a shareholders meeting will be convened between February 27 and March 13, 2026.
Additional Highlights for Q3FY26
- 13% YoY overall revenue growth with strong international revenue.
- 11% YoY Operating EBITDA growth driven by improved performance in Kerala and Lab business.
- Healthy growth in Oncology revenue by 27% YoY, contributing to 11% of revenue.
- Added 320+ beds, largely driven by 263 beds added in MIMS Kasargod.
Pipeline Projects
Total addition of 4,080+ beds, bringing the total bed capacity to 14,710+ beds.
- FY26: 234 beds
- FY27: 944 beds
- FY28: 1,877 beds
- Beyond FY28: 1,030 beds
Merger Implementation Progress
- In November 2024, Company announced merger of Quality Care.
- Company has received shareholders’ approval, CCI approval and stock exchange approval.
- Expected timeline for the completion of the Merger: Q1FY27.
Source: BSE
